CoChat

Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis

Open access
Jin, Ying, Fu, Jian · 2019 · Journal of the American Heart Association
Cited by 148

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

A therosclerosis underlies the leading cause of death in industrialized countries. Atherosclerosis is a maladaptive, nonresolving chronic inflammatory disease that occurs predominantly at sites of disturbed laminar flow, notably, arterial branch points and bifurcations, of large and mediumsized arteries. Atherosclerosis is initiated by subendothelial buildup of apolipoprotein B–containing lipoproteins (in particular LDL [low-density lipoprotein]). LDL, particularly following oxidation, has properties of damage-associated molecular patterns and thereby provokes the activation of endothelial cells (ECs) and ensuing recruitment of blood-borne monocytes to the lesion. The Ly6C subpopulation of monocytes differentiates into macrophages. Serving to protect the organism against tissue damage, macrophages have developed plasticity to tailor the inflammatory responses. In short, macrophages have the capacity to trigger inflammation when necessary and to quell the inflammatory response when it is no longer required. In the atherosclerotic milieu, macrophages are predominantly polarized to an inflammatory phenotype. Lipid-loaded cells known as foam cells constitute a hallmark of atherosclerotic lesion, which can be detected at very early stages of atherosclerosis. The causal role for metabolic stress factors such as LDL, particularly oxidized LDL (oxLDL) and cholesterol, in promoting vascular inflammation and atherosclerosis has long been appreciated. However, the precise mechanism whereby metabolic stress elicits the proinflammatory status and induces atherogenesis remained unclear. When resolution of inflammation goes awry, nonresolving inflammation characterizes the atherosclerotic lesions. The mechanisms behind the nonresolving nature of vascular inflammation in the atherosclerotic lesion remain to be entirely defined. The inflammatory environment incurs apoptosis of intimal cells. Defective efferocytosis, a process by which phagocytic cells (predominantly macrophages) engulf the dead cells, promotes the formation of the necrotic core. Immune responses are further amplified by relentless production of damage-associated molecular patterns from necrotic cells in the advanced lesions. Innate immunity plays crucial roles in plaque initiation, progression, and rupture. It has been well established that the inflammasomes constitute an important component of innate immunity. The term inflammasome was first coined by Jurg Tschopp and his colleagues in 2002 to explain the mechanism for caspase-1 activation and interleukin-1b processing. To date, diverse inflammasomes have been discovered. Among the various inflammasomes identified, the nucleotide-binding oligomerization domain, leucine-rich repeat–containing receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome is best characterized. The groundbreaking findings that the NLRP3 inflammasome is a key player in orchestrating lipid-driven vascular inflammation and plays a fundamental role in the initiation and progression of atherogenesis are transforming the field of atherosclerosis. The focus of this review is on our current understanding of the role, regulation, and mechanisms of NLRP3 inflammasome activation in atherosclerosis. We will also discuss the therapeutic potential of NLRP3 inflammasome intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.119.012219

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 148

Metadata

Authors
Jin, Y., & Fu, J.
Venue
Journal of the American Heart Association
Published
2019-06-18
Volume
8
Issue
12
Pages
e012219-e012219
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2950956897
Cited by
148
References
31
FWCI
4.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.